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NanoparticlesAbstract High performance liquid chromatographic method was optimized, developed and vali-
dated as per the ICH guidelines. In this study the 20 mM ammonium formate and acetonitrile in
the 57:43 ratio were used as mobile phase for the analysis of valsartan. Full factorial design was
used to optimize the effect of variable factors. The responses were peak area, tailing factor and
number of theoretical plates. The quadratic effect of ﬂow rate and wavelength individually as well
as in interaction were most signiﬁcant (p< 0.0001 and p< 0.0086, respectively) on peak area; the
quadratic effect of pH of buffer was also most signiﬁcant effect (p< 0.0001) on tailing factor (5%)
whereas the quadratic effect of ﬂow rate and wavelength individually was signiﬁcant (p= 0.0006
and p= 0.0265, respectively) on the number of theoretical plates. The high-performance liquid
chromatographic separation was performed at the ﬂow rate 1.0 min/mL, UV detector wavelength
250 nm and pH of the buffer 3.0 as optimized parameters using design of experiments. The retention
time values of valsartan were found to be 10.177 min. Percent recovery in terms of accuracy for the
prepared valsartan nanoparticles was found in the range of 98.57–100.27%.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nowadays cardiovascular disorders are the main cause of
deaths not only in developing countries, but all over the world.
Cardiovascular disorders are associated with coronary heartdisease, hypertension, ischemic heart disease, cerebrovascular
disease, rheumatic heart disease, heart failure, high cholesterol
levels, etc. As per the trends of deaths in developing countries
due to this disorder around 1.5 billion deaths have been pro-
jected by 2015 (Grundy et al., 2004; Kearney et al., 2005;
Gonzalez et al., 2009; Solanki et al., 2014). Hypertension is a
key factor underlying cardiovascular disorder. Numerous
antihypertensive drugs are available for the management of
hypertension. Angiotensin II receptor (subtype AT1) blockers
are the mainly used drugs for the management of hyperten-
sion. Valsartan is an example of angiotensin II receptor
antagonist (Grundy et al., 2004), but its main problem is its
low bioavailability (10–30%) which is because of its low
550 L. Kumar et al.aqueous solubility. This drug comes under BCS class II means
it has low solubility and high permeability. To improve the
solubility of this drug investigator has prepared the nanoparti-
cles of drug. For the analysis of drug in nano-formulations the
investigator has developed a new HPLC method.
HPLC method suitability is based upon the validation part.
As per ICH guidelines, speciﬁcity, linearity, accuracy, preci-
sion, limits of detection (LOD) and limit of quantitation
(LOQ) are the main parts of a new method validation (Ye
et al., 2000; ICH Harmonized Tripartite Guideline and
Methodology Q2 (R1), 2005).
The method for the analysis of drug in the nanoformulation
should be enough robust, sensitive and precise; hence, in this
method design of experiment has been applied to study the effect
of factors individually and in combination also. Design of
experiment (DOE) is based upon the principles of experimental
design, mathematical equations or models and outcomes of the
factors. This research article focuses on the optimization,
development and validation of a new analytical method with
DOE.
In this work, an analytical HPLC method has been opti-
mized, developed and validated with DOE for the determina-
tion of valsartan in nano-formulations.
2. Experimental
2.1. Instrumentation
HPLC system consisted of a Shimadzu Corporation, Kyoto,
Japan, LC-2010CHT model connected to PDA (Photodiode
array, model no. SPD-M20A PDA with 220–230 V,
Shimadzu Corporation, Kyoto, Japan) and dual wavelength
UV detector, column oven and auto sampler (Shimadzu
Corporation, Kyoto, Japan) was used in this study.
Chromatograms were recorded by a computer and treated
with the aid of LC solution 5.57 release.
A HyperClone (Phenomenex) C18 column (250 mm ·
4.6 mm id, 5 lm, BDS 130 A˚) was used to perform the sep-
aration, with a C18 Phenomenex, 4 · 3.0 mm id, security
guard column.
The mobile phase was ﬁltered through theMillipore glass ﬁl-
ter (Millipore ﬁlter cellulose nitrate grided with 0.22 l size and
47 mm diameter) assembly attached with vacuum pump. The
mobile phase was sonicated with Ultrasonic Cleaner – 15L
(Equitron – Medica Instrument Mfg. Co., Mumbai, India).
The pH of mobile phase or buffer was measured with Eutech
Instruments pH 510 using a glass electrode Van London Co.,
USA.
High pure water (18.2 MX cm resistivity, Milli-Q) was pro-
duced with a Direct-Q 3 water puriﬁcation system, Millipore
Corporation (Billerica, MA, USA).
2.2. Chemical and solvents
Valsartan was obtained from Lupin Ltd. (Goa, India) as a gift
sample. Ammonium formate was purchased from Sisco
research Laboratories Pvt. Ltd. (Mumbai, India). Formic acid
was purchased from RFCL Limited (New Delhi, India).
Acetonitrile HPLC Grade was purchased from Finar
Limited (Ahmadabad, India). Methanol HPLC Grade was
purchased from Labort Fine Chem Pvt. Ltd. (Surat, India).High pure water (18.2 MX cm resistivity, Milli-Q) was pro-
duced with a Direct-Q 3 water puriﬁcation system,
Millipore Corporation (Billerica, MA, USA).
2.3. Preparation of buffer for mobile phase
Ammonium formate buffer was prepared for mobile phase.
The 20 mM ammonium formate buffer solution was prepared
by dissolving pre-calculated amount of ammonium formate in
1000 mL Milli Q water and the pH 3.0 was adjusted with for-
mic acid. The formic acid is also used as a solvent which helps
to improve the peak characteristics (Grumbach et al., 2004;
Yang et al., 2010; Solanki et al., 2014). Then the prepared buf-
fer was passed through 0.22 l ﬁlter.
2.4. Preparation of mobile phase
Mobile phase was used in the combination of buffer:acetoni-
trile ratio 57:43. The ammonium formate was used for the pre-
paration of mobile phase, because it is volatile in nature and
does not get precipitated in column and HPLC system
(Dolan, 2014). Hence, the chances of development of high
back pressure are less. The mobile phase was passed through
the ﬁlter with 0.22 l pore size and was sonicated for 15 min
before pumping into HPLC system for degassing.
2.5. Optimization and development of HPLC method
In the present study, C18 silica packed HPLC column was used
for better separation. A HyperClone (Phenomenex) C18
column (250 mm · 4.6 mm id, 5 lm, BDS 130 A˚) was used to
perform the separation, with a C18 Phenomenex,
4 · 3.0 mm id, security guard column. In order to avoid
column’s high internal pressure, acetonitrile was used as an
organic solvent, because of its low viscosity.
The ﬂow rate, pH of buffer solution and wavelength play
an important role in HPLC method. Hence, in the present
study, these three factors were optimized based on DOE.
Valsartan is a weak acidic drug and has approximately 4.9
pKa value (Cagigal et al., 2001). Three different pH of ammo-
nium formate such as 2.8, 3.0 and 3.2 were studied and opti-
mized with DOE. This pH was used in the study for best
retention of acidic drug in a reversed-phase system. For best
retention, the pH of buffer or the mobile phase should be
approx. two pH units below its pKa value (Dolan, 2014). In this
pH the drug will be totally unionized (more hydrophobic) which
helps for better retention in a reversed-phase system. Themobile
phase was selected in 57:43 ratio of buffer:acetonitrile. The 20 ll
injection volume was used in the study. The UV detector was
used for detection of drug in the samples. As like pH, three
different wavelengths such as 248, 250 and 252 nm were studied
and one wavelength was selected based on DOE. Similarly, the
effect of ﬂow rate (i.e. 0.8, 1.0 and 1.2 mL/min) was studied and
based on DOE, the ﬁnal ﬂow rate was selected.
Most of the formulation studies involve only one variant at
a time by keeping others as constant. With the help of full fac-
torial design investigators can study the effect of all the factors
by varied simultaneously. The factorial design helps to study
the effects caused by independent factors and interactions
between those self-governing factors (Bozkir and Saka,
2005). In the present work, three independent factors were
Table 1 Planned 33 full factorial designs for robustness study.
Independent factors Levels
1 0 +1
Flow rate (mL/min) 0.8 1.0 1.2
Wavelength (nm) 248 250 252
pH of buﬀer 2.8 3.0 3.2
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(C). Three factorial levels were used in the study and
were coded as 1, 0 and +1 for low, medium and high,
respectively (Singh et al., 1995, 2008; Nagarwal et al.,
2009; Yahiaoui and Aissani-Benissad, 2010). Totally 27
experimental runs were suggested by the software for analyz-
ing the interaction of each level on formulation characters
and the peak area (R1), tailing factor (5%) (R2) and number
of theoretical plate USP (NTP) (R3) were considered as
response factors (dependent factors). Tables 1 and 2 show
the factors chosen and different factor level settings. The
signiﬁcance of independent factors was determined using
Fisher’s statistical test for Analysis of the Variance
(ANOVA) model that was estimated.
The polynomial equation for the experimental design with
three factors is given below:
R ¼ b0 þ b1Aþ b2Bþ b3Cþ b2ABþ b2ACþ b2BCþ b2A2
þ b2B2 þ b2C2:
where R is the response, b is the regression coefﬁcients and A,
B and C represent ﬂow rate, wavelength and pH of buffer,
respectively.Table 2 33 Full factorial designs for robustness study.
Run Independent variables
Flow rate (mL/min) Wavelength (nm) pH of buﬀer
Run 1 0.8 248 2.8
Run 2 1.0 248 2.8
Run 3 1.2 248 2.8
Run 4 0.8 250 2.8
Run 5 1.0 250 2.8
Run 6 1.2 250 2.8
Run 7 0.8 252 2.8
Run 8 1.0 252 2.8
Run 9 1.2 252 2.8
Run 10 0.8 248 3.0
Run 11 1.0 248 3.0
Run 12 1.2 248 3.0
Run 13 0.8 250 3.0
Run 14 1.0 250 3.0
Run 15 1.2 250 3.0
Run 16 0.8 252 3.0
Run 17 1.0 252 3.0
Run 18 1.2 252 3.0
Run 19 0.8 248 3.2
Run 20 1.0 248 3.2
Run 21 1.2 248 3.2
Run 22 0.8 250 3.2
Run 23 1.0 250 3.2
Run 24 1.2 250 3.2
Run 25 0.8 252 3.2
Run 26 1.0 252 3.2
Run 27 1.2 252 3.22.6. Validation of HPLC method
The developed and optimized method was validated as per the
ICH Q2 (R1) guidelines for following parameters such as lin-
earity, accuracy, precision, limit of detection (LOD) and limit
of quantitation (LOQ) (Solanki et al., 2014; ICH Harmonized
Tripartite Guideline and Methodology Q2 (R1), 2005).
2.6.1. System suitability
For system suitability determination 6 lg/mL of valsartan was
used as stock solution. Six replicate injections of this standard
solution were analyzed with HPLC. From these replicate injec-
tions, the acceptance criteria for peak area, tailing factor (5%),
tailing factor (10%) and number of theoretical plate were
studied.
2.6.2. Linearity
The standard calibration curve was prepared with different
concentrations from 0.1 to 12 lg/mL. Three replicate injec-
tions of each concentration were analyzed for this study. The
linear regression and correlation coefﬁcient were found out
from the graph between peak area and concentration.
2.6.3. Precision
The precision is a study which is based upon the intra-day pre-
cision and inter-day precision. Precision of the developed
method was evaluated by performing repeatability (six times
of each concentration) of three distinct concentrations two
times in a day (i.e. morning and evening) whereas the
intermediate precision study was performed by repeating three
distinct concentrations on two different days. Intra-day and
inter-day precision was performed by using three unusual
concentrations such as 1, 6 and 12 lg/mL. The peak area
was measured and percent relative standard deviation (%
RSD) was calculated (Rajput and Sonanis, 2011).
2.6.4. Accuracy
The accuracy of developed method was studied by determining
recovery values. The term accuracy means the value which is
near to the value of reference. For the determination of accu-
racy, the standard drug in the range of 75%, 100% and 125%
of the sample’s concentration (2 lg/mL) was mixed with sam-
ple solution, which produces the ﬁnal concentration 3, 4 and-1.000 -0.500 0.000 0.500 1.000
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Figure 1 Effect of ﬂow rate (A), wavelength (B) and pH of buffer
(C) on peak area (R1).
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Figure 2 Effect of ﬂow rate (A), wavelength (B) and pH of buffer
(C) on tailing factor (R2).
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Figure 3 Effect of ﬂow rate (A), wavelength (B) and pH of buffer
(C) on number of theoretical plates (R3).
552 L. Kumar et al.5 lg/mL. The same process has been performed in triplicate.
The percent recovery (Sagirli et al., 2007) of the added stan-
dard drug to the assay samples was calculated with the follow-
ing formula:
Percent recovery ¼ ½ðCc  CfÞ=Cs  100
where Cc is the concentration of analyte present in the
combination of standard and test; Cf is the concentration of
analyte in nano-formulation and Cs is the concentration of
standard analyte used in the combination.
2.6.5. Limit of detection and limit of quantitation
The sigma method was used for the limit of detection (LOD)
(Awotwe-Otoo et al., 2012). This method is based upon the
slope and least standard deviation obtained from the response.
The formula for the calculation of LOD used was
LOD= 3.3r/SP, where r is the minutest standard deviation
value in response and SP is the slope of the calibration curve.
Similarly, the limit of quantitation (LOQ) was also calculated
from the response of valsartan. The formula for the calculation
of LOQ used was LOQ= 10r/SP, where r is the least stan-
dard deviation value in response and SP is the slope of the
response.
3. Results and discussion
3.1. Development and optimization of HPLC method
In this study, the 27 runs were performed, and results were
obtained for peak area, tailing factor (5%) and number of
theoretical plates. The perturbation plots were created using
Design Expert version 9.0.3.1 software to estimate the effect
of factors on peak area, tailing factor and number of theoreti-
cal plates.
Perturbation plots bear the effect of self-governing factors
on the dependent factors. Fig. 1 is related to the effect of
independent factors on peak area. It shows that there is no
effect of wavelength (B) and pH of buffer (C) on peak area,
but the ﬂow rate (A) shows an incredible effect on peak area
as the increase in the ﬂow rate decreases the peak area.
Fig. 2 gives the information about the effect of independent
factors on tailing factor (5%). This ﬁgure shows that there is
no effect of ﬂow rate and wavelength on tailing factor, but
pH of buffer plays an important role on the same as when
the pH increases, the tailing factor also increases.
Fig. 3 informs the effect of independent factors on the num-
ber of theoretical plate. Figure shows that as the ﬂow rate and
buffer pH increase the number of theoretical plate decreases,
whereas with the increase in the wavelength, there is a slight
increase in the number of theoretical plate.
Similarly, the peak area, tailing factor (5%) and number of
theoretical plates of each injection were entered in Design
Expert version 9.0.3.1 software and analyzed using the
ANOVA with its signiﬁcance method. For an experimental
design with three variable factors, the suitable model ﬁtting
to the data was the quadratic model. The polynomial equa-
tions for the response factors are given below:
Peak area (R1) =+(3.261E + 005)  68744.94A 
2848.56B+ 325.83C  91.58AB  1326.42AC  269.92BC+
13321.83A2 + 1468.33B2 + 27.17C2.Tailing factor (R2) = +1.14  (1.111E003)A+ (1.111E
004)B+ 0.039C+ (2.500E004)AB  (2.917E003)AC 
(1.167E003)BC  (2.222E004)A2 + (1.111E004)B2 +
0.011C2.
Number of theoretical plate (R3) = +12240.15 
1937.06A  57.33B  1124.67C+ 52.75AB  748.33AC+
3.33BC  528.94A2 + 1108.89B2  578.11C2.
where R1, R2 and R3 are the response factors i.e. peak area,
tailing factor and number of theoretical plate, respectively. The
A, B and C are the ﬂow rate, wavelength and pH of buffer,
respectively.
The quadratic effect of ﬂow rate and wavelength separately
as well as in interaction was most signiﬁcant (p< 0.0001 and
p< 0.0086, respectively) on peak area; the quadratic effect of
pH of buffer was also most signiﬁcant effect (p< 0.0001) on
tailing factor (5%) whereas the quadratic effect of ﬂow rate
and wavelength individually was signiﬁcant (with p= 0.0006 and
p= 0.0265, respectively) on the number of theoretical plates.
3.2. Validation of optimized factors
The results of optimized independent variable such as ﬂow
rate, wavelength and pH of buffer were validated by
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Figure 4 The 3D surface response plot of desirability for
optimization of factors.
Table 3 Validation of optimized factors.
Response Predicted results Observed results Residual values (%)
Peak area 326,124 360,930 10.673
Tailing factor (5%) 1.1452 1.103 +3.685
Number of theoretical plate 12240.1 13,219 7.997
Full factorial design for optimization, development and validation of HPLC method 553comparing the predicted results and observed results. The dif-
ference between the predicted and the observed results was
found within ±11% as shown in Table 3. The formula used
to calculate the percent residual value is
Percent residual ¼ Predicted resultsObserved results
Predicted results
 100
The desirability of the optimized factor is shown in Fig. 4.
The desirability values usually exist in the range of 0–1. If the
value is near to zero means the solution of the method is not
strong whereas the value toward 1 side means the solution or
method is very strong. The found desirability value was maxi-
mum (i.e. 1) which indicates the method is highly strong.
3.3. Method validation
3.3.1. Selectivity
The study has been performed as per the ICH Q2 (R1) guide-
lines (ICH Harmonized Tripartite Guideline and MethodologyFigure 5 Chromatogram of blankQ2 (R1), 2005). The chromatogram of blank and 6 lg/mL
concentration of valsartan is shown in Fig. 5. The retention
time of the drug was found to be 10.177 min.
3.3.2. System suitability
System suitability was expressed by percent relative standard
deviations of peak area, tailing factor (5%), tailing factor
(10%) and number of theoretical plate. System suitability
was carried out by performing six replicates of 6 lg/mL.
The% RSD of peak area, tailing factor (5%), tailing factor
(10%) and number of theoretical plate results is reported in
Table 4. The % RSD value of peak area, tailing factor
(10%) and number of theoretical plate was found to be less
than 0.5% and % RSD value of tailing factor (5%) was found
to be <1%.
3.3.3. Linearity
The standard calibration curve over the valsartan concentra-
tion range 0.1–12 lg/mL shows r2 = 0.9976 which is an
acceptable value for correlation coefﬁcients. The linear regres-
sion from the above gives concentration range that was found
to be y= 54061x+ 10210.
3.3.4. Precision
Precision of new developed method was evaluated by intra-day
and inter-day precision and was expressed by percent relative
standard deviations of peak area. Intra-day and inter-day pre-
cision was carried out by performing six replicates of 1, 6 and
12 lg/mL. The % RSD of peak area of intra-day and inter-day
precision results is reported in Table 5. The % RSD value of
intra-day precision (all three concentrations) was found to be
less than 1% and % RSD value of inter-day precision (all three
concentrations) was found to be <2%.
3.3.5. Accuracy
The accuracy study has been performed by the addition of
standard drug in samples at three different concentration levels(Data 2) and valsartan (Data 1).
Table 4 System suitability test using 6 lg/mL.
S no. Parameters Results
Mean SD % RSD
1 Peak area 363052.300 1245.4620 0.343
2 Tailing factor (5%) 1.114 0.0067 0.606
3 Tailing factor (10%) 1.092 0.0039 0.361
4 Number of theoretical plate 13153.500 49.6659 0.378
Table 5 Intra-day and inter-day precision of valsartan.
S no. Conc. (lg/mL) Intra-day precision Inter-day precision
Mean area SD % RSD Mean area SD % RSD
1 1.0 60148.08 512.65 0.85 59316.92 809.18 1.36
2 6.0 360614.70 3150.57 0.87 357362.60 2292.19 0.64
3 12.0 637475.00 4276.53 0.67 636835.40 5108.63 0.80
554 L. Kumar et al.such as 75%, 100% and 125%. The percent recovery at these
three different concentration levels was found in the range of
98.57–100.27%. This study suggests a suitable method for
the routine experimental analysis of drug in the formulations.
3.3.6. Limit of detection and limit of quantitation
The limit of detection and limit of quantitation were deter-
mined by the sigma method. The limits of detection and limit
of quantitation were found to be 14.833 ng/mL and 44.95
ng/mL, respectively.4. Conclusion
The method was successfully developed and optimized through
DOE, and data were analyzed using Design Expert version
9.0.3.1 software. The signiﬁcant effect of independent factors
was analyzed using ANOVA, and the effect was also reported
in the form of perturbation plots. The design of experiments
provides efﬁcient tools for the optimization of variable factors
for HPLC method development. Further the method was
validated and as per the results, the present method is novel,
simple, accurate, precise, economic and robust for the analysis
of valsartan in nanoformulations.
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